1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Pfizer Launches US Bevacizumab At A 23% Discount

Zirabev Biosimilar Rival To Avastin Will Ship From Next Week

 
• By Dave Wallace

Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.

23Off
Pfizer’s Zirabev Will Be Available At A 23% Discount To Avastin • Source: Shutterstock

Pfizer has revealed a “substantially discounted price” for its Zirabev (bevacizumab-bvzr) biosimilar rival to Avastin that the firm is getting ready to ship in the US this month.

“Pfizer has priced Zirabev at a wholesale acquisition cost of $61

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.